Deidre Dalmas

Company: CPATH-PSTC

Job title: Scientific Director, US Investigative Safety, Nonclinical Safety Project Lead, Fellow

Bio:

Dr. Deidre Dalmas, is an innovative Pharmaceutical industry thought leader with expertise in investigative and mechanistic toxicology, translational safety and biomarker development, and application across drug discovery and development (D&D). A pioneer in novel in vitro/in vivo/Insilco assay development, application and integration of spatial biology, spatial transcriptomics/multi-omics to systems such as CIVMs, MPS systems samples across all stages of D&D. She leads global D&D initiatives and serves in leadership roles as a Pharmaceutical Industry Representative across multiple cross-industry consortia including CPATH-PSTC (Predictive Safety Testing Consortium), HESI-eSTAR (Emerging Systems Toxicology for the Assessment of Risk), and NASA’s CASIS Science User Advisory Committee advancing predictive safety tools and multi-omics integration across drug discovery and development. Her work bridges advanced science with regulatory strategy, accelerating the development and adoption of predictive safety tools and enabling better understanding of mechanisms of toxicity. She is passionate about advancing innovative technologies that reduce drug attrition and improve patient outcomes through safer, more effective therapeutics.

Seminars:

Roundtable Discussion: Building Better Partnerships for Robust Results to Unlock Scalable Spatial Biology 2:40 pm

Defining what makes an effective spatial biology partner to ensure robust, reproducible results Setting clear standards for workflows, data sharing, and validation to ensure reproducibility and trust Building long-term frameworks for cross-functional collaboration that drive adoption and real-world impactRead more

day: Day One

Panel Discussion: What Will it Take to Standardize Spatial Across Industry & Who Should Lead the Charge? 9:40 am

What are the most critical barriers currently preventing standardization across spatial platforms, workflows, and datasets in biopharma? How do inconsistent tissue handling, assay protocols, and data formats affect cross-study comparability and regulatory acceptance? Should standardization start with biomarkers, instrumentation, data pipelines, or all at once? What should the priority be?Read more

day: Day One